MGTXMeiraGTx Holdings plc

Healthcare

$9.19+13% 1Y

$9.19

$6.9952 weeks$14.96

Is the price fair?

Good

Undemanding: modest expectations priced in and cheap vs its sector.

2 good, 1 without data

What the price assumes~+25% a year

Priced for ~25% a year FCF growth. The price demands less than its three-year revenue growth of 296% a year, expectations look modest.

Vs sector (EV/EBIT)4.6×

Sector median 25.1× across 135 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.

All from derived, as of Jun 30, 2026.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

P/E (valuation)better than 79% of the market

FCF yieldbottom 6% of the market

Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.

What MGTX's price assumes

MeiraGTx Holdings plc trades at 12.9× earnings against 19.8× for the median Biotechnology name, cheaper than its own group.

12.9

Trailing P/E · Biotechnology median 19.8 · cheaper than the typical name in its group

Price / sales: 2.22
Price / sales · today's price, trailing year to Jun 30, 2026
Free cash flow yield: 1.2%
Free cash flow yield · Biotechnology median 4.3%
Growth the price implies: +25%
Growth the price implies · The price pays for +25% free cash flow growth a year for a decade; revenue has grown 296% a year over the last three.